European regulators are investigating the risk of suicidal thoughts associated with popular weight-loss drugs.
European regulators are investigating the risk of suicidal thoughts associated with popular weight-loss drugs.
Investigating the Link Between Weight-Loss Drugs and Suicidal Thoughts
Weight-loss drugs have long been a popular choice for individuals looking to shed a few pounds. However, recent reports have raised concerns about the potential link between certain weight-loss drugs and suicidal thoughts or self-harm. The European Medicines Agency (EMA) is currently investigating these concerns, following three case reports from Iceland that highlighted the issue.
The EMA, Europe’s equivalent of the U.S. Food and Drug Administration (FDA), is conducting a thorough review of weight-loss drugs such as Ozempic and Saxenda. Two cases of suicidal thoughts were reported after using Ozempic (semaglutide), while the third case involved Saxenda (liraglutide) and thoughts of self-injury. Both drugs are manufactured by Novo Nordisk, a leading pharmaceutical company.
Novo Nordisk has responded to these concerns by emphasizing its commitment to patient safety. The company takes all reports of adverse events seriously and is working closely with regulatory agencies like the EMA and the FDA to ensure the safety of their medications.
Interestingly, while Saxenda’s prescribing information includes a recommendation to monitor patients for depression or suicidal thoughts, Ozempic does not carry a similar warning. However, Wegovy, another weight-loss drug containing the same active ingredient as Ozempic, does include information about reports of suicidal behavior and ideation in clinical trials with other weight-management medications.
These weight-loss drugs belong to a class known as GLP-1 receptor agonists and are designed to stimulate the release of insulin, resulting in lower blood sugar levels and slowed digestion. Saxenda, approved for weight loss in 2014, has previously been associated with suicidal ideation in clinical trials. Nine individuals out of 3,300 reported suicidal ideation while taking Saxenda, while two individuals out of 1,900 reported suicidal ideation when on a placebo during those same trials.
- Testing the entire genome is twice as effective as targeted tests i...
- 1/3 of American couples opt for ‘sleep divorce’ for bet...
- 1 in 5 say work is toxic
Moreover, Saxenda’s prescribing information even includes a case of an adult attempting suicide. However, it is important to note that the prescribing information states there is insufficient information to establish a causal relationship between Saxenda and the suicide attempt. Additionally, in pediatric clinical trials, one person died by suicide out of 125 participants. Again, the causal relationship to Saxenda was uncertain.
Given these concerning reports, it is crucial for healthcare providers to closely monitor patients taking weight-loss medications for any signs of depression, suicidal thoughts, or unusual changes in mood or behavior. The prescribing information for Wegovy emphasizes the need for regular monitoring and raises awareness about potential mental health side effects.
The FDA, similar to the EMA, takes adverse event reports seriously and evaluates them on an ongoing basis. While it does not comment on third-party research as a general matter, the FDA routinely evaluates individual reports and adverse event reports from the published literature for all approved drugs.
As the EMA investigates these weight-loss drugs, there is a possibility that the review may extend beyond Ozempic and Saxenda to other GLP-1 receptor agonists like Wegovy and Eli Lilly’s Mounjaro. The safety committee will carefully consider all available evidence and make recommendations based on their findings.
It is important for individuals considering weight-loss drugs to have open and honest conversations with their healthcare providers. They should discuss the potential risks and benefits associated with these medications, and healthcare providers should closely monitor patients for any mental health changes during treatment.
Ultimately, the goal is to prioritize patient safety and ensure that weight-loss drugs are used responsibly and effectively in conjunction with proper medical supervision. With ongoing research and evaluations by regulatory agencies, the medical community can continue to gain valuable insights into the potential risks and benefits of these medications.
Source: CNN
### [SLIDESHOW] The Best Diet Tips: How to Lose Weight the Healthy Way
